Cancer, immunodeficiency and antiretroviral treatment: Results from the Australian HIV Observational Database (AHOD)

K. Petoumenos; M.T. van Leuwen; C.M. Vajdic; I. Woolley; J. Chuah; D.J. Templeton; A.E. Grulich; M.G. Law; D. Nolan

doi:10.1111/j.1468-1293.2012.01038.x

Back

Cancer, immunodeficiency and antiretroviral treatment: Results from the Australian HIV Observational Database (AHOD)

Journal article

Open access

Peer reviewed

Cancer, immunodeficiency and antiretroviral treatment: Results from the Australian HIV Observational Database (AHOD)

K. Petoumenos, M.T. van Leuwen, C.M. Vajdic, I. Woolley, J. Chuah, D.J. Templeton, A.E. Grulich, M.G. Law and D. Nolan

HIV Medicine, Vol.14(2), pp.77-84

2012

DOI: https://doi.org/10.1111/j.1468-1293.2012.01038.x

Files and links (2)

pdf

cancers AHOD.pdfDownload View

Published (Version of Record) Open Access

url

Link to Published Version *Subscription may be requiredView

Abstract

The objective of the study was to conduct a within-cohort assessment of risk factors for incident AIDS-defining cancers (ADCs) and non-ADCs (NADCs) within the Australian HIV Observational Database (AHOD).A total of 2181 AHOD registrants were linked to the National AIDS Registry/National HIV Database (NAR/NHD) and the Australian Cancer Registry to identify those with a notified cancer diagnosis. Included in the current analyses were cancers diagnosed after HIV infection. Risk factors for cancers were also assessed using logistic regression methods.One hundred and thirty-nine cancer cases were diagnosed after HIV infection among 129 patients. More than half the diagnoses (n = 68; 60%) were ADCs, of which 69% were Kaposi's sarcoma and 31% non-Hodgkin's lymphoma. Among the NADCs, the most common cancers were melanoma (n = 10), lung cancer (n = 6), Hodgkin's lymphoma (n = 5) and anal cancer (n = 5). Over a total of 21021 person-years (PY) of follow-up since HIV diagnosis, the overall crude cancer incidence rate for any cancer was 5.09/1000 PY. The overall rate of cancers decreased from 15.9/1000 PY [95% confidence interval (CI) 9.25-25.40/1000 PY] for CD4 counts < 100 cells/μL to 2.4/1000 PY (95% CI 1.62-3.39/1000 PY) for CD4 counts > 350 cells/μL. Lower CD4 cell count and prior AIDS diagnoses were significant predictors for both ADCs and NADCs.ADCs remain the predominant cancers in this population, although NADC rates have increased in the more recent time period. Immune deficiency is a risk factor for both ADCs and NADCs.

Details

Title: Cancer, immunodeficiency and antiretroviral treatment: Results from the Australian HIV Observational Database (AHOD)
Authors/Creators: K. Petoumenos (Author/Creator) - Kirby Institute
M.T. van Leuwen (Author/Creator) - UNSW Sydney
C.M. Vajdic (Author/Creator) - UNSW Sydney
I. Woolley (Author/Creator) - Monash Medical Centre
J. Chuah (Author/Creator) - Nashotah House Theological Seminary
D.J. Templeton (Author/Creator) - Kirby Institute
A.E. Grulich (Author/Creator) - Kirby Institute
M.G. Law (Author/Creator) - Kirby Institute
D. Nolan (Author/Creator)
Publication Details: HIV Medicine, Vol.14(2), pp.77-84
Publisher: Blackwell Publishing
Identifiers: 991005540243907891
Murdoch Affiliation: Murdoch University
Language: English
Resource Type: Journal article
Additional Information: David Nolan appears courtesy of the Australian HIV Observational Database

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Metrics

180 File views/ downloads

54 Record Views

24 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.130 Lymphomas; 1.130.1220 Kaposi
Web Of Science research areas: Infectious Diseases
ESI research areas: Immunology